Manufacturing failures in cell and gene therapy (CGT) carry high costs and risks, jeopardizing the timely production and delivery of safe, effective, and scalable allogeneic therapies. Dr. Yuki Kato Maves presents a real-world case study highlighting how Discovery Life Sciences partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs). This initiative significantly reduces the risk of failure and CDMO costs, showcasing the transformative impact of streamlined processes on CGT production success.
Speaker Information:
Yuki Kato Maves, Ph.D., Director, Product Management, Discovery Life Sciences